Protease‐activated receptor‐1 drives pancreatic cancer progression and chemoresistance

Protease activated receptor (PAR)‐1 expression in tumor cells is associated with disease progression and overall survival in a variety of cancers of epithelial origin; however, the importance of PAR‐1 in the tumor microenvironment remains unexplored. Utilizing an orthotopic pancreatic cancer model in which tumor cells are PAR‐1 positive whereas stromal cells are PAR‐1 negative, we show that PAR‐1 expression in the microenvironment drives progression and induces chemoresistance of pancreatic cancer. PAR‐1 enhances monocyte recruitment into the tumor microenvironment by regulating monocyte migration and fibroblast dependent chemokine production thereby inducing chemoresistance. Overall, our data identify a novel role of PAR‐1 in the pancreatic tumor microenvironment and suggest that PAR‐1 may be an attractive target to reduce drug resistance in pancreatic cancer.

[1]  D. Richel,et al.  Protease‐activated receptor‐2 induces migration of pancreatic cancer cells in an extracellular ATP‐dependent manner , 2013, Journal of thrombosis and haemostasis : JTH.

[2]  Hengyi Xiao,et al.  Anti‐tumour strategies aiming to target tumour‐associated macrophages , 2013, Immunology.

[3]  V. Heinemann,et al.  Systemic treatment of advanced pancreatic cancer. , 2012, Cancer treatment reviews.

[4]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[5]  P. Insel,et al.  Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease‐activated receptor 1, in cardiac fibroblasts , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  M. Peppelenbosch,et al.  Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  D. H. Cox,et al.  Suppression of Arterial Thrombosis Without Affecting Hemostatic Parameters With a Cell-Penetrating PAR1 Pepducin , 2012, Circulation.

[8]  N. Akar,et al.  The Association of Protease Activated Receptor 1 gene −506 I/D Polymorphism with Disease-Free Survival in Breast Cancer Patients , 2012, Annals of Surgical Oncology.

[9]  D. Tuveson,et al.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.

[10]  L. Coussens,et al.  Differential macrophage programming in the tumor microenvironment. , 2012, Trends in immunology.

[11]  Gerald C. Chu,et al.  Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma , 2011, Proceedings of the National Academy of Sciences.

[12]  Xi-lin Du,et al.  Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. , 2011, Japanese journal of clinical oncology.

[13]  John Yang,et al.  Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. , 2011, The American journal of pathology.

[14]  F. Finkelman,et al.  Local Macrophage Proliferation, Rather than Recruitment from the Blood, Is a Signature of TH2 Inflammation , 2011, Science.

[15]  S. Natsugoe,et al.  Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. , 2011, The Journal of surgical research.

[16]  Zhao-You Tang,et al.  Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.

[17]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Maitra,et al.  The hedgehog pathway and pancreatic cancer. , 2009, The New England journal of medicine.

[19]  A. Agarwal,et al.  Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. , 2009, Cancer research.

[20]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[21]  R. Johns,et al.  Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. , 2009, American journal of respiratory and critical care medicine.

[22]  A. Sood,et al.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.

[23]  T. Goi,et al.  Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. , 2008, Anticancer research.

[24]  R. Chambers Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? , 2008, British journal of pharmacology.

[25]  M. Hollenberg,et al.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more , 2008, British journal of pharmacology.

[26]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[27]  Eithne Costello,et al.  Biology and management of pancreatic cancer , 2007, Postgraduate Medical Journal.

[28]  Ralph H. Hruban,et al.  Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer , 2007, Clinical Cancer Research.

[29]  R. Vessella,et al.  Overexpression of protease‐activated receptors‐1,‐2, and‐4 (PAR‐1, ‐2, and ‐4) in prostate cancer , 2007, The Prostate.

[30]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[31]  D. V. Von Hoff,et al.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.

[32]  G. Scagliotti,et al.  Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer. , 2006, Clinical lung cancer.

[33]  M. Hollenberg,et al.  Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. , 2005, Human pathology.

[34]  R. Johns,et al.  Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. , 2005, The American journal of pathology.

[35]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[36]  Z. Salah,et al.  Differential expression of Protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples , 2005, International journal of cancer.

[37]  T. Sawada,et al.  A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. , 2004, International journal of oncology.

[38]  M. Laburthe,et al.  Protease-activated Receptor 2 in Colon Cancer , 2004, Journal of Biological Chemistry.

[39]  G. Caliendo,et al.  PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation , 2004, Hepatology.

[40]  G. Neufeld,et al.  Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Ogawa,et al.  Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. , 2003, International journal of oncology.

[42]  S. Coughlin,et al.  A Role for Thrombin Receptor Signaling in Endothelial Cells During Embryonic Development , 2001, Science.

[43]  M. D'Andrea,et al.  Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. , 2001, The American journal of pathology.

[44]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[45]  M. Nakagawa,et al.  Prognostic value of tumor‐associated macrophage count in human bladder cancer , 2000, International journal of urology : official journal of the Japanese Urological Association.

[46]  T. Billiar,et al.  Nitric Oxide Inhibits Apoptosis by Preventing Increases in Caspase-3-like Activity via Two Distinct Mechanisms* , 1997, The Journal of Biological Chemistry.

[47]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Coughlin,et al.  The Cloned Thrombin Receptor Is Necessary and Sufficient for Activation of Mitogen-activated Protein Kinase and Mitogenesis in Mouse Lung Fibroblasts , 1996, The Journal of Biological Chemistry.

[49]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[50]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[51]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[52]  P. Reitsma,et al.  Cardiovascular , Pulmonary and Renal Pathology Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation , 2010 .

[53]  P. Bioulac-Sage,et al.  Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis. , 2008, American journal of physiology. Gastrointestinal and liver physiology.